Literature DB >> 9891464

Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer.

A J Karayiannakis1, K N Syrigos, E Chatzigianni, S Papanikolaou, D Alexiou, N Kalahanis, T Rosenberg, E Bastounis.   

Abstract

E-cadherin is a cell-cell adhesion molecule involved in tumour invasion and metastasis. We evaluated E-cadherin expression immunohistochemically in 43 formalin-fixed, paraffin-embedded specimens of pancreatic cancer and investigated its relationship to histopathological features. In non-cancerous pancreatic cells E-cadherin immunoreactivity was localized at the cell membrane, particularly at the intercellular junctions. Abnormal E-cadherin expression was found in 18 (42%) cases. A significantly higher proportion of poorly-differentiated tumours (71%) showed abnormal E-cadherin expression compared with moderately (50%) and well (19%) differentiated tumours (P = 0.037). There was a significant correlation between abnormal E-cadherin expression and lymph node involvement (P = 0.013), the presence of distant metastases (P = 0.034) and advanced tumour stage (P = 0.025). These findings suggest that loss of normal E-cadherin expression is involved in the progression of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891464

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

Review 1.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Lack of association of cadherin expression and histopathologic type, metastasis, or patient outcome in oropharyngeal squamous cell carcinoma: a tissue microarray study.

Authors:  O C Ukpo; W L Thorstad; Q Zhang; J S Lewis
Journal:  Head Neck Pathol       Date:  2011-11-10

Review 3.  Genes that regulate metastasis and angiogenesis.

Authors:  C P Webb; G F Vande Woude
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.

Authors:  Alexander P Stark; Hui-Hua Chang; Xiaoman Jung; Aune Moro; Kathleen Hertzer; Mu Xu; Andrea Schmidt; O Joe Hines; Guido Eibl
Journal:  Surgery       Date:  2015-08-18       Impact factor: 3.982

5.  The clinicopathological significance and potential drug target of E-cadherin in NSCLC.

Authors:  Kaize Zhong; Weiwen Chen; Ning Xiao; Jian Zhao
Journal:  Tumour Biol       Date:  2015-03-11

6.  microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.

Authors:  Zhao-li Chen; Xiao-hong Zhao; Ji-wen Wang; Bao-zhong Li; Zhen Wang; Jian Sun; Feng-wei Tan; Da-peng Ding; Xiao-hui Xu; Fang Zhou; Xiao-gang Tan; Jie Hang; Su-sheng Shi; Xiao-li Feng; Jie He
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

7.  Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer.

Authors:  Yu-Jun Li; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.

Authors:  Tracy Murray-Stewart; Patrick M Woster; Robert A Casero
Journal:  Amino Acids       Date:  2013-03-19       Impact factor: 3.520

9.  Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.

Authors:  Jordan M Winter; Angela H Ting; Felip Vilardell; Eike Gallmeier; Steve B Baylin; Ralph H Hruban; Scott E Kern; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

Review 10.  Regulation of EMT by KLF4 in gastrointestinal cancer.

Authors:  Jiujie Cui; Min Shi; Ming Quan; Keping Xie
Journal:  Curr Cancer Drug Targets       Date:  2013-11       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.